DOI: 10.3310/nihropenres.14234.1 ISSN: 2633-4402

The effectiveness, cost consequences, and safety of 5 versus 7 days of oral flucloxacillin for lower limb cellulitis in adults presenting in UK primary care: study protocol for the COAT trial - a pragmatic, multicentre, double-blind, randomised, phas

Ella Bourke, Zina Eminton, Kerensa Thorne, Sophie Varkonyi-Clifford, Charlotte Stuart, Taeko Becque, Nick Levell, Miriam Santer, Kim Thomas, Paul Little, Theo Verheij, Robert Read, Tracey Sach, Beth Stuart, Jacqui Nuttall, Andrew Cook, Richard Stephens, Graham Bartram, Nick Francis
Show PDF Cite
Background Cellulitis is an acute bacterial infection of the dermis and subcutaneous tissue, most commonly affecting the lower limbs. UK guidelines recommend a 5–7-day course of oral flucloxacillin as first-line treatment in primary care. Most patients are prescribed a 7-day course or longer. Evidence supporting shorter regimens is limited and largely derived from hospital-based studies using alternative antimicrobial agents. No trials have evaluated different durations of oral flucloxacillin in primary care. This trial aims to assess the effectiveness, safety, and cost consequences of 5 versus 7 days of oral flucloxacillin for lower limb cellulitis in UK primary care. Methods This is a pragmatic, phase III, multi-centre, randomised, double-blind, non-inferiority trial, with internal pilot and parallel health economic evaluation. Adults (≥18 years) with lower-limb cellulitis will be randomised (1:1) to 5 vs 7 days of oral flucloxacillin, operationalised by providing 500 mg flucloxacillin or matched placebo, four times daily for two days following completion of a 5-day standard-of-care course of open-label flucloxacillin. Participants will be followed up for 28 days using self-reported symptom diaries and at 12 months through medical notes review. The primary outcome is pain over days 6–14 post-baseline, recorded daily on a 0–10 Numerical Rating Scale. Secondary outcomes include total antibiotic and analgesic use, patient-reported wellbeing, health-related quality of life, severity of leg swelling and redness, time to self-reported recovery, healthcare resource use (including hospital admissions, primary care consultations, and medication), recurrent cellulitis episodes, complications, and participant-incurred costs. The primary analysis will compare pain scores between groups using a generalised linear mixed model, adjusting for baseline pain and stratification variables and accounting for clustering of repeated measures within participants. The trial received ethical approval from the North East – Tyne & Wear South Research Ethics Committee on 16 June 2023 (ref: 23/NE/0021). Trial registration ISRCTN27053187, 01/06/2023, https://doi.org/10.1186/ISRCTN27053187

More from our Archive